Litigation Details for Currax Pharmaceuticals LLC v. MSN Laboratories Private Limited (D. Del. 2020)

« Back to Dashboard

Currax Pharmaceuticals LLC v. MSN Laboratories Private Limited (D. Del. 2020)

Docket		Date Filed	2020-08-13
Court	District Court, D. Delaware	Date Terminated	2022-11-16
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Jennifer L. Hall
Parties	CURRAX PHARMACEUTICALS LLC
Patents	10,548,871; 10,653,660; 7,915,307; 9,532,971; 9,572,814; 9,907,780
Attorneys	Neal C. Belgam
Firms	Venable LLP
Link to Docket	External link to docket

Details for Currax Pharmaceuticals LLC v. MSN Laboratories Private Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-13				External link to document
2020-08-13	31	Notice of Service	Contentions for U.S. Patent Nos. 7,915,307, 9,532,971, 9,572,814, 9,907,780, 10,548,871, and 10,653,660 filed… 16 November 2022 1:20-cv-01064 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Currax Pharmaceuticals LLC v. MSN Laboratories: Contrave Patent Litigation Analysis, Case No. 1:20-cv-01064

Last updated: August 15, 2026

Currax Pharmaceuticals sued MSN Laboratories Private Limited in the District of Delaware after MSN submitted an abbreviated new drug application seeking approval for a generic version of Contrave, an extended-release combination of naltrexone hydrochloride and bupropion hydrochloride used for chronic weight management. The case was one of several ANDA actions filed by Currax against generic manufacturers.

The dispute concerned patent protection for Contrave’s composition, extended-release formulation, and methods of treating obesity. The case was litigated under the Hatch-Waxman framework and was assigned to Judge Richard G. Andrews under Case No. 1:20-cv-01064-RGA. Public docket materials indicate that the action ended without a reported merits judgment establishing invalidity or noninfringement of the asserted patents.[1]

What drug and FDA approval were involved in the MSN litigation?

The product was Contrave, marketed by Currax Pharmaceuticals.

Item	Information
Brand	Contrave
Active ingredients	Naltrexone hydrochloride and bupropion hydrochloride
Dosage form	Extended-release tablets
FDA indication	Chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity
NDA	200063
Original FDA approval	September 2014
Plaintiff	Currax Pharmaceuticals LLC
Defendant	MSN Laboratories Private Limited
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01064-RGA
Filing period	2020
Proceeding type	Hatch-Waxman ANDA litigation

Contrave combines an opioid antagonist, naltrexone, with the antidepressant and smoking-cessation drug bupropion. The formulation uses extended-release delivery and requires a dose-escalation schedule because of safety and tolerability considerations.[2]

The FDA-approved label limits the product’s use to adults with an initial body-mass index of at least 30, or at least 27 when a weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia is present. The label also contains contraindications relating to uncontrolled hypertension, seizure risk, opioid use, and abrupt discontinuation of alcohol or sedatives.[2]

What patents protected Contrave in Currax v. MSN?

Currax’s Contrave patent estate included patents directed to the combination of naltrexone and bupropion, extended-release pharmaceutical compositions, and methods of treating obesity. The patents most closely associated with Contrave’s Orange Book protection included the following:

Patent	General subject matter	Relevance to Contrave
U.S. Patent No. 8,628,921	Naltrexone and bupropion combination compositions and treatment methods	Core combination-product protection
U.S. Patent No. 9,675,587	Treatment of obesity using naltrexone and bupropion	Method-of-use protection
U.S. Patent No. 10,034,938	Combination drug product and extended-release formulation subject matter	Product and formulation protection

Patent scope and listing status must be assessed from the specific Orange Book edition and the asserted claims identified in the complaint. A patent’s presence in the Orange Book does not establish that every claim is valid or infringed. It gives the NDA holder a statutory basis to bring an infringement action after receiving an ANDA notice containing a Paragraph IV certification.[3]

The commercial value of the estate came from claim layering. A generic applicant could challenge the active-ingredient combination, the release profile, the tablet composition, and the approved obesity indication through separate invalidity and noninfringement theories. A successful challenge to one patent would not necessarily eliminate every barrier to approval.

Why did Currax sue MSN Laboratories?

MSN’s ANDA certification triggered Currax’s infringement action. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Under the Hatch-Waxman statute, the filing of an infringement action within 45 days of receiving the ANDA notice generally triggers a 30-month stay of FDA approval, subject to statutory exceptions.[3]

Currax’s claims would have been based on MSN’s proposed generic product and the information contained in the ANDA. Typical allegations in this type of case include:

1. Composition claims covering the naltrexone-bupropion combination.
2. Formulation claims covering extended-release delivery.
3. Method-of-use claims covering treatment of obesity or weight management.
4. Induced or contributory infringement theories based on the proposed prescribing information.

The litigation did not concern whether Contrave was safe or effective. FDA approval and patent infringement are separate inquiries. The FDA evaluates the generic’s pharmaceutical equivalence, bioequivalence, labeling, manufacturing controls, and safety-related requirements. The district court evaluates patent validity, enforceability, and infringement.

What was the procedural history of Case No. 1:20-cv-01064?

The case followed the standard sequence for a branded-drug patent action:

Event	Significance
Currax complaint filed in 2020	Initiated infringement litigation based on MSN’s ANDA certification
MSN answer and defenses	Put validity, enforceability, and infringement at issue
Claim-construction and discovery phase	Would have addressed the meaning of disputed patent terms and ANDA technical information
Hatch-Waxman approval stay	Restricted FDA approval of MSN’s ANDA for the statutory period unless the stay was shortened or lifted
Disposition by stipulation or dismissal	Ended the district-court action without a reported trial judgment

The public record does not identify a reported district-court opinion holding the asserted Contrave patents invalid or not infringed by MSN. The action therefore should not be treated as a precedent resolving the patent estate on the merits.

The absence of a merits decision is commercially important. A dismissal or settlement can preserve uncertainty about patent validity and may leave the parties’ market-entry rights dependent on confidential settlement terms, FDA approval timing, and the status of related cases against other ANDA applicants.

Did MSN bring a Paragraph IV challenge?

Yes. The case was an ANDA patent action, which indicates that MSN’s proposed generic product was presented to the FDA with a patent certification placing Currax’s listed Contrave patents at issue.

A Paragraph IV challenge does not automatically mean that the generic applicant will launch before patent expiry. The applicant may:

• Obtain a court ruling of invalidity or noninfringement.
• Resolve the dispute through a settlement with a negotiated launch date.
• Wait for patent expiration or delisting.
• Launch at risk after the statutory stay ends.
• Revise the ANDA or labeling to avoid an asserted method-of-use claim.

For Contrave, the principal generic-entry question was not limited to whether MSN could copy the active ingredients. The proposed product also had to satisfy extended-release performance requirements and avoid infringement of formulation and use claims.

What was the Orange Book status of Contrave?

Contrave’s Orange Book listings gave Currax a basis to enforce listed patents against ANDA applicants. The relevant Orange Book questions include:

• Which patents were listed for NDA 200063?
• Whether each patent covered the drug substance, drug product, or method of use.
• Whether a patent had expired, been delisted, or remained enforceable.
• Whether the generic applicant carved out any patented indication under section viii.
• Whether the ANDA applicant made a Paragraph III or Paragraph IV certification.

Orange Book listing is particularly important for method-of-use patents. A generic applicant may seek approval for unpatented uses while carving out a patented indication from its labeling. That strategy is more difficult when the patented use is integrated into the product’s principal commercial indication or when the label still encourages infringement.

The FDA Orange Book does not determine claim construction or patent validity. It is an FDA listing and regulatory reference, not a substitute for a district-court judgment.[4]

When does Contrave lose exclusivity?

Contrave has different exclusivity dates depending on the legal right being analyzed.

FDA regulatory exclusivity

Contrave received approval in 2014. New chemical entity exclusivity generally lasts five years, subject to the timing of ANDA submissions and Paragraph IV exceptions. That period is separate from patent protection and is no longer the primary barrier to generic entry for Contrave.[3]

Patent exclusivity

Patent expiry depends on the specific listed patent, applicable patent-term adjustment or extension, terminal disclaimers, and the Orange Book’s current listing data. The estate was designed to extend protection beyond the basic approval period through later-issued formulation and method-of-use patents.

A business assessment should therefore distinguish:

Exclusivity category	Effect on generic entry
NCE exclusivity	Blocks certain ANDA submissions during the statutory period
Listed drug-product patent	Can trigger a 30-month FDA approval stay after timely litigation
Method-of-use patent	May support a full-label challenge or require a section viii carve-out
Formulation patent	Can block a therapeutically substitutable extended-release product
Patent settlement	May permit an agreed launch date before patent expiry
Pediatric exclusivity	Adds six months only if granted and applicable

The litigation record alone does not establish MSN’s authorized launch date. A launch date would depend on the settlement terms, patent status, any shared exclusivity arrangements, and FDA approval.

What formulation patents were important?

The formulation issues were commercially significant because Contrave is not a simple immediate-release tablet. Its value depends on delivering both active ingredients in an extended-release regimen while maintaining acceptable pharmacokinetic and safety characteristics.

Formulation patent issues can include:

• The ratio of naltrexone to bupropion.
• Separate or combined release characteristics.
• Tablet matrix composition.
• Dissolution profiles.
• Dose escalation and maintenance dosing.
• Stability and manufacturing parameters.
• Bioequivalence to the reference listed drug.

A generic applicant can sometimes avoid a formulation claim by modifying excipients, release mechanisms, tablet architecture, or manufacturing processes. That strategy must still produce an FDA-acceptable product that is therapeutically equivalent to Contrave. The closer the generic product must remain to the reference product’s release profile, the greater the potential overlap with formulation claims.

What method-of-use patents affected generic entry?

Contrave method-of-use claims generally target treatment of obesity or weight management with the naltrexone-bupropion combination. Such claims can be valuable even when composition claims face an earlier expiration date.

Method-of-use patents create two principal litigation paths:

1. Full-label approval: the generic seeks approval for the same obesity indication and faces direct infringement allegations.
2. Section viii carve-out: the generic removes patented use information from its labeling and seeks approval only for unpatented indications.

The effectiveness of a carve-out depends on the proposed label, physician prescribing behavior, promotional activity, and whether the remaining label would encourage use covered by the patent. Currax could argue induced infringement if the generic label or distribution practices encouraged use for the patented obesity indication.

What was the likely business impact of the litigation?

Contrave was an important commercial asset for Currax because the company’s portfolio is concentrated in branded weight-management products. Generic entry would likely pressure price, payer coverage, prescription volume, and net revenue.

The principal commercial scenarios were:

Scenario	Market effect
Currax wins on all asserted claims	Generic approval delayed until relevant patent barriers expire
MSN wins on validity or infringement	Earlier generic entry and rapid price erosion
Settlement with delayed entry	Predictable erosion date and reduced litigation risk
Carved-out approval	Potentially narrower competition, depending on label and prescribing
At-risk launch	Immediate price pressure and possible damages exposure if Currax later prevails

Generic entry into a branded extended-release combination product can produce rapid gross-price reductions, but the net effect depends on payer substitution, pharmacy benefit design, generic manufacturer capacity, and whether multiple ANDA applicants enter at the same time.

How strong was the Contrave patent estate?

The estate had moderate structural strength because it used multiple claim categories rather than relying on a single composition patent. The most defensible claims in a combination-product case are often those tied closely to the approved product’s physical characteristics and validated release profile. Method-of-use claims can add duration but may face carve-out and induced-infringement issues.

Strength factor	Assessment
Multiple patent categories	Positive
Extended-release formulation	Potentially strong if claim limitations track the approved product
Method-of-use claims	Valuable but vulnerable to carve-out strategies
Later-issued patents	Can extend nominal protection but may face priority and obviousness challenges
ANDA technical overlap	Depends on MSN’s actual formulation and dissolution data
Reported merits ruling	None identified in the public case record
Settlement uncertainty	High if dismissal terms were confidential

The strongest business conclusion is that the MSN case did not produce a public invalidity judgment that would broadly weaken Currax’s Contrave estate. At the same time, the absence of a merits ruling means the case does not affirmatively validate the patents.

Were there licensing deals or settlement agreements?

The public docket disposition does not provide a reported, detailed settlement opinion establishing the economic terms of any resolution between Currax and MSN. If the case ended through a confidential settlement, the agreement may have addressed:

• A permitted generic launch date.
• Patent-litigation releases.
• Authorized-generic restrictions.
• Supply or licensing rights.
• Allocation of 180-day exclusivity risk.
• Mutual dismissal of claims and counterclaims.

Settlement terms in ANDA cases often determine the practical exclusivity period more directly than the nominal patent expiration date. A confidential settlement should not be assumed to authorize immediate entry merely because the district-court case was dismissed.

Did the case involve biosimilar risk?

No. Biosimilar law was not relevant to this action.

Contrave is a small-molecule combination drug, not a biologic. MSN’s product was pursued through the ANDA pathway under the Hatch-Waxman Act, not through the Biologics Price Competition and Innovation Act. The competitive threat was generic substitution, not biosimilar interchangeability.

Which companies were competing with Contrave?

Contrave competed in the chronic weight-management market with other prescription therapies, including:

• Wegovy, semaglutide, marketed by Novo Nordisk.
• Saxenda, liraglutide, marketed by Novo Nordisk.
• Qsymia, phentermine/topiramate, marketed by Vivus and later commercial partners.
• Xenical and Alli, orlistat products.
• Imcivree, setmelanotide, for specific genetic obesity disorders.

The competitive risk from GLP-1 therapies was broader than generic substitution. Even before generic Contrave entry, GLP-1 products placed pressure on prescribing, payer budgets, and treatment sequencing. A generic Contrave launch would add price competition within the oral anti-obesity segment.

Key Takeaways

• Currax sued MSN Laboratories in Delaware over an ANDA for generic Contrave.
• Contrave contains extended-release naltrexone hydrochloride and bupropion hydrochloride.
• The litigation implicated composition, formulation, and method-of-use patent protection.
• The case was a Paragraph IV Hatch-Waxman action and likely triggered the statutory FDA approval stay.
• No reported merits judgment established that the asserted Contrave patents were invalid or not infringed.
• The action’s disposition did not publicly disclose a detailed commercial settlement or authorized launch date.
• Biosimilar analysis is irrelevant because Contrave is a small-molecule drug.
• Generic-entry risk depends on the Orange Book listing status, settlement terms, remaining patent life, and the number of approved ANDAs.
• Contrave faces both generic competition risk and broader therapeutic competition from GLP-1 obesity medicines.

FAQs

Can MSN launch generic Contrave immediately after the case ended?

Not necessarily. Case dismissal does not itself establish FDA approval, patent clearance, or an agreed launch date. The launch position depends on the ANDA’s regulatory status, applicable patents, and any settlement agreement.

Did Currax obtain a judgment confirming Contrave patent validity?

No reported judgment in Case No. 1:20-cv-01064 establishes the validity of the asserted Contrave patents after trial or summary judgment.

Are Contrave’s patents drug-product patents or method-of-use patents?

The Contrave estate included both product or formulation protection and method-of-use protection directed to treatment of obesity with naltrexone and bupropion.

Could a generic manufacturer avoid Contrave method-of-use patents?

A manufacturer may attempt a section viii label carve-out for patented uses. The strategy depends on the exact patent claims, the proposed label, and whether the remaining label encourages infringement.

Is Contrave exposed to biosimilar competition?

No. Contrave is a small-molecule combination product. Its relevant competitive threat is generic ANDA approval, not biosimilar approval.

References

1. U.S. District Court for the District of Delaware. (2020). Currax Pharmaceuticals LLC v. MSN Laboratories Private Limited, No. 1:20-cv-01064-RGA. PACER docket records.
2. U.S. Food and Drug Administration. (2023). Contrave prescribing information.
3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
5. U.S. Patent and Trademark Office. (2024). Patent public search database.